Compare Stocks

The Strive Enhanced Income Short Maturity ETF (BUXX) is an exchange-traded fund that mostly invests in broad credit fixed income. The fund is actively managed, investing in a portfolio of various fixed-income securities of any credit rating from issuers all around the globe. The fund aims for a dollar-weighted average maturity of less than two years BUXX was launched on Aug 10, 2023 and is issued by Alpha Architect.

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.

The Fidelity Low Duration Bond ETF (FLDB) is an exchange-traded fund that mostly invests in investment grade fixed income. The fund is an actively managed fund of investment-grade, domestic and foreign fixed income securities with broad maturities. It aims to maintain a dollar-weighted average portfolio maturity of two years or less, and duration of one year or less. FLDB was launched on Feb 22, 2024 and is issued by Fidelity.

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.